IMMIX BIOPHARMA INC (IMMX) Stock Price, Quote, News and Overview
NASDAQ:IMMX - Nasdaq - US45258H1068 - Common Stock - Currency: USD
IMMX Quote, Performance and Key Statistics
2.71
-0.08 (-2.87%)
The current stock price of IMMX is 2.71 USD. In the past month the price increased by 20.98%. In the past year, price increased by 20.98%.
IMMX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.53 | 336.11B | ||
| AMGN | AMGEN INC | 14.77 | 164.85B | ||
| GILD | GILEAD SCIENCES INC | 15.01 | 144.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.71 | 60.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.87B | ||
| ARGX | ARGENX SE - ADR | 102.95 | 36.23B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.72B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.29B | ||
| INSM | INSMED INC | N/A | 19.72B | ||
| BIIB | BIOGEN INC | 8.31 | 19.27B |
Related stock screener links
About IMMX
Company Profile
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 18 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Company Info
IMMIX BIOPHARMA INC
11400 West Olympic Blvd., Suite 200
Los Angeles CALIFORNIA US
Employees: 16
Phone: 18889581084
IMMIX BIOPHARMA INC / IMMX FAQ
What is the stock price of IMMIX BIOPHARMA INC today?
The current stock price of IMMX is 2.71 USD. The price decreased by -2.87% in the last trading session.
What is the ticker symbol for IMMIX BIOPHARMA INC stock?
The exchange symbol of IMMIX BIOPHARMA INC is IMMX and it is listed on the Nasdaq exchange.
On which exchange is IMMX stock listed?
IMMX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMIX BIOPHARMA INC stock?
7 analysts have analysed IMMX and the average price target is 7.14 USD. This implies a price increase of 163.47% is expected in the next year compared to the current price of 2.71. Check the IMMIX BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMIX BIOPHARMA INC worth?
IMMIX BIOPHARMA INC (IMMX) has a market capitalization of 75.47M USD. This makes IMMX a Micro Cap stock.
How many employees does IMMIX BIOPHARMA INC have?
IMMIX BIOPHARMA INC (IMMX) currently has 16 employees.
What are the support and resistance levels for IMMIX BIOPHARMA INC (IMMX) stock?
IMMIX BIOPHARMA INC (IMMX) has a support level at 2.7 and a resistance level at 2.98. Check the full technical report for a detailed analysis of IMMX support and resistance levels.
Is IMMIX BIOPHARMA INC (IMMX) expected to grow?
The Revenue of IMMIX BIOPHARMA INC (IMMX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the IMMX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMIX BIOPHARMA INC (IMMX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMMX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMMX, evaluating the profitability, health, valuation and growth aspects
- IMMIX BIOPHARMA INC (IMMX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMIX BIOPHARMA INC (IMMX) Sales and EPS estimates to see what analysts future expectations are.
- IMMIX BIOPHARMA INC (IMMX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMIX BIOPHARMA INC (IMMX) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMIX BIOPHARMA INC (IMMX) Stock Chart to make your own analysis
- IMMIX BIOPHARMA INC (IMMX) Latest news and press-releases to stay up to date.
Does IMMIX BIOPHARMA INC (IMMX) stock pay dividends?
IMMX does not pay a dividend.
When does IMMIX BIOPHARMA INC (IMMX) report earnings?
IMMIX BIOPHARMA INC (IMMX) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of IMMIX BIOPHARMA INC (IMMX)?
IMMIX BIOPHARMA INC (IMMX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
What is the Short Interest ratio of IMMIX BIOPHARMA INC (IMMX) stock?
The outstanding short interest for IMMIX BIOPHARMA INC (IMMX) is 1% of its float. Check the ownership tab for more information on the IMMX short interest.
IMMX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IMMX. When comparing the yearly performance of all stocks, IMMX is one of the better performing stocks in the market, outperforming 87.16% of all stocks.
IMMX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMMX. While IMMX seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMMX Financial Highlights
Over the last trailing twelve months IMMX reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 23.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.05% | ||
| ROE | -217.82% | ||
| Debt/Equity | 0 |
IMMX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to IMMX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 19.38% and a revenue growth -100% for IMMX